Influenza A virus exploits the cellular transport machinery during the early stages of infection. It enters cells by endocytosis and takes advantage of the endocytic trafficking to move towards the perinuclear region with the assistance of actin filaments and microtubules. A recent proteomic study identified vimentin as a putative interacting protein of influenza viral components. However, the role of vimentin during influenza A infection has not yet been determined. After endocytosis, the viral ribonucleopotein complexes (vRNPs), containing the RNA viral genome, the viral polymerases, and several copies of nucleoprotein, are released from late endosomes and enter the nucleus for replication. Two nuclear localization sequences (NLSs), NLS1 ...
Influenza virus rapidly evolves to evade vaccines and gain resistance to antiviral therapies. Yearly...
Influenza A virus (IAV) proteins interact with an array of cellular proteins and hijack host pathway...
Influenza virus rapidly evolves to evade vaccines and gain resistance to antiviral therapies. Yearly...
Influenza A virus exploits the cellular transport machinery during the early stages of infection. It...
Background: Early in infection, the genome of the influenza A virus, consisting of ...
Background: The influenza A virus replicates in the nucleus of its host cell. Thus,...
The influenza A virus nucleoprotein (NP) is an essential multifunctional protein that encapsidates t...
Influenza A viruses (IAV) are obligate intracellular pathogens, causing substantial health and econo...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: Influenza A virus non-structural protein 1 (...
The nuclear pore complex (NPC) mediates the bidirectional transport of macromolecules across the nuc...
The influenza A viral ribonucleoprotein (vRNP) is a macromolecular complex composed of nucleoprotein...
Influenza A viruses can cause fatal respiratory infections. The viral ribonucleoprotein (vRNP) is re...
Influenza A viruses have a single-stranded RNA genome consisting of 8 segments. Each RNA segment ass...
The diverse functions of the influenza virus nucleoprotein (NP) are thought to depend on its phospho...
Influenza B virus is an enveloped negative-strand RNA virus that contributes considerably to annual ...
Influenza virus rapidly evolves to evade vaccines and gain resistance to antiviral therapies. Yearly...
Influenza A virus (IAV) proteins interact with an array of cellular proteins and hijack host pathway...
Influenza virus rapidly evolves to evade vaccines and gain resistance to antiviral therapies. Yearly...
Influenza A virus exploits the cellular transport machinery during the early stages of infection. It...
Background: Early in infection, the genome of the influenza A virus, consisting of ...
Background: The influenza A virus replicates in the nucleus of its host cell. Thus,...
The influenza A virus nucleoprotein (NP) is an essential multifunctional protein that encapsidates t...
Influenza A viruses (IAV) are obligate intracellular pathogens, causing substantial health and econo...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: Influenza A virus non-structural protein 1 (...
The nuclear pore complex (NPC) mediates the bidirectional transport of macromolecules across the nuc...
The influenza A viral ribonucleoprotein (vRNP) is a macromolecular complex composed of nucleoprotein...
Influenza A viruses can cause fatal respiratory infections. The viral ribonucleoprotein (vRNP) is re...
Influenza A viruses have a single-stranded RNA genome consisting of 8 segments. Each RNA segment ass...
The diverse functions of the influenza virus nucleoprotein (NP) are thought to depend on its phospho...
Influenza B virus is an enveloped negative-strand RNA virus that contributes considerably to annual ...
Influenza virus rapidly evolves to evade vaccines and gain resistance to antiviral therapies. Yearly...
Influenza A virus (IAV) proteins interact with an array of cellular proteins and hijack host pathway...
Influenza virus rapidly evolves to evade vaccines and gain resistance to antiviral therapies. Yearly...